Zoetis Inc. ZTS
Set alert
As of Nov 2, 10:45 AM ET
- YTD
- -35.13%
- 1 year
- -43.36%
- Open
- 80.15
- Prev close
- 79.72
- Mkt cap
- 33.72B
- Vol
- 826.65K
- Avg vol
- 4.98M
- EPS
- 6.08
- P/E
- 13.42
- Div yield
- 2.69%
More statistics
- Low
- 79.89
- High
- 82.09
- Forward P/E
- 12.44
- Beta
- 0.74
- Short ratio
- 3.99
- Inst. own
- 100.27%
- Dividend
- 2.12
- Ex-div date
- Oct 29, 2026
- Earnings
- Nov 5, 2026
- 50-d avg
- 74.95
- 200-d avg
- 93.76
- 1y target
- 88.38
5D chart
Events in this range
- Oct 27, 2026Rating: UBS · Neutral → Neutral
- Oct 29, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 30, 2026Dividend: 0.53
Signals (90)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 10:40 AM | 5 minutes ago |
| SMA: Bearish | Nov 2, 10:25 AM | 20 minutes ago |
| RSI: Overbought | Nov 2, 10:00 AM | 45 minutes ago |
| SMA: Bullish | Nov 2, 9:30 AM | 1 hour ago |
| RSI: Overbought | Nov 2, 9:30 AM | 1 hour ago |
| MACD: Buy Signal | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:40 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:25 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| RSI: Overbought | Oct 30, 12:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 30, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 4:00 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:45 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:25 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:15 PM | 3 days ago |
| RSI: Overbought | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:05 PM | 4 days ago |
| RSI: Oversold | Oct 28, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:15 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 3:30 PM | 5 days ago |
| RSI: Oversold | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| RSI: Oversold | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
News
3 days ago zacks.com
Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Zoetis (ZTS) closed at $78.8, indicating a +1.29% shift from the previous trading day.
-
3 days ago benzinga.com
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $82
Morgan Stanley analyst Erin Wright maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $85 to $82.
5 days ago zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
-
5 days ago benzinga.com
UBS Maintains Neutral on Zoetis, Raises Price Target to $85
UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and raises the price target from $80 to $85.
5 days ago fool.com
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
The stocks listed here yield up to 5.8%.
1 week ago fool.com
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
1 week ago zacks.com
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Zoetis (ZTS) closed at $81.03, marking a -1.18% move from the previous day.
1 week ago zacks.com
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.
1 week ago businesswire.com
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.
1 week ago benzinga.com
This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Werner, Zoetis, Apple, Heartland Express and Elanco, cutting ratings to Neutral/Hold and lowering price targets.
-
1 week ago benzinga.com
Jefferies Downgrades Zoetis to Hold, Lowers Price Target to $83
Jefferies analyst Keith Devas downgrades Zoetis (NYSE:ZTS) from Buy to Hold and lowers the price target from $103 to $83.
1 week ago 247wallst.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and More
Apple just got cut, BlackRock got a lift, and chipmakers are under pressure ahead of a week packed with big-tech earnings. Find out which stocks Wall Street is moving on Tuesday and why the calls…
2 weeks ago defenseworld.net
8,293 Zoetis Inc. $ZTS Shares Sold by Banque Pictet & Cie SA
Banque Pictet and Cie SA reduced its holdings in shares of Zoetis Inc. (NYSE: ZTS) by 0.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and…
-
2 weeks ago benzinga.com
Goldman Sachs Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $74
Goldman Sachs analyst Matt Dellatorre initiates coverage on Zoetis (NYSE:ZTS) with a Neutral rating and announces Price Target of $74.
2 weeks ago businesswire.com
Zoetis Appoints Iris Knobloch to its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With…
3 weeks ago seekingalpha.com
10 Dividend Growth Stocks: October 2026
In this monthly series, I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. This month's screen targets dividend growth stocks with Dividend Safety scores…
3 weeks ago seekingalpha.com
Top 50 High-Quality Dividend Growth Stocks For October 2026
I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home…
3 weeks ago zacks.com
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
In the most recent trading session, Zoetis (ZTS) closed at $74.81, indicating a +2.37% shift from the previous trading day.
3 weeks ago fool.com
A Once-in-a-Decade Opportunity: 2 Magnificent Dividend Stocks Down 34% to 52% I'm Buying Right Now
Whether you want a higher 3% dividend yield or a quickly growing dividend that yields 1.2%, these two stocks look like rare opportunities.
3 weeks ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 weeks ago businesswire.com
Zoetis Declares Fourth Quarter 2026 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will…
3 weeks ago businesswire.com
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows…
3 weeks ago benzinga.com
Zoetis Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Zoetis (NYSE:ZTS) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For…
3 weeks ago defenseworld.net
40,294 Zoetis Inc. $ZTS Shares Purchased by Rockland Trust Co.
Rockland Trust Co. boosted its stake in Zoetis Inc. (NYSE: ZTS) by 19.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 244,065…
1 month ago zacks.com
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.
1 month ago seekingalpha.com
Zoetis: Priced For The Worst, Worth Buying
Zoetis Inc. (ZTS) has fallen 71% from its 2021 peak, now trading at 2017 levels, as pricing power eroded and pet medicine volumes declined. Despite near-term headwinds, Zoetis maintains…
1 month ago zacks.com
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
2 months ago benzinga.com
Stifel Maintains Hold on Zoetis, Lowers Price Target to $80
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target from $85 to $80.
-
2 months ago benzinga.com
FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies
https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-treat-new-world-screwworm-dogs-and-puppies
-
2 months ago benzinga.com
BNP Paribas Maintains Outperform on Zoetis, Lowers Price Target to $110
BNP Paribas analyst Navann Ty maintains Zoetis (NYSE:ZTS) with a Outperform and lowers the price target from $146 to $110.
-
2 months ago benzinga.com
Piper Sandler Maintains Neutral on Zoetis, Lowers Price Target to $80
Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target from $90 to $80.
2 months ago benzinga.com
5 Stock Picks Last Week From Wall Street's Most Accurate Analysts
U.S. stocks close higher on Friday, with Nasdaq up 300 points and S&P 500 at record high. Benzinga's Analyst Ratings API can aid in stock picks.
-
2 months ago benzinga.com
UBS Maintains Neutral on Zoetis, Lowers Price Target to $80
UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target from $85 to $80.
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Zoetis, Lowers Price Target to $115
JP Morgan analyst Chris Schott maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $130 to $115.
2 months ago benzinga.com
Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds
Zoetis beat second-quarter earnings estimates but missed on revenue, cut 2026 guidance and cited weaker pet health demand and pricing pressure.
-
2 months ago benzinga.com
Zoetis Lowers FY2026 Adj EPS Guidance from $6.85-$7.00 to $6.15-$6.25 vs $6.88 Est; Lowers FY2026 Sales Guidance from $9.680B-$9.960B to $9.120B-$9.320B vs $9.726B Est
Zoetis (NYSE:ZTS) lowers FY2026 Adj EPS guidance from $6.85-$7.00 to $6.15-$6.25 vs $6.88 analyst estimate. Lowers FY2026 sales outlook from $9.680 billion-$9.960 billion to $9.120 billion-$9.320…
-
2 months ago benzinga.com
Zoetis Q2 Adj. EPS $1.87 Beats $1.86 Estimate, Sales $2.468B Miss $2.502B Estimate
Zoetis (NYSE:ZTS) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $1.86 by 0.54 percent. This is a 6.25 percent increase over earnings of $1.76 per share…
3 months ago benzinga.com
Michael Burry Expands Bets Against Nvidia, Micron— and Is Now Buying Lululemon and DraftKings
Michael Burry expands short positions against Nvidia and AI, while piling into de-risked value stocks like Lululemon and DraftKings.
-
3 months ago benzinga.com
UBS Maintains Neutral on Zoetis, Lowers Price Target to $85
UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target from $99 to $85.
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $99
Morgan Stanley analyst Erin Wright maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $115 to $99.
-
3 months ago benzinga.com
Zoetis Commercially Rolls Out Portela In Canada, EU To Treat Pain Associated With Osteoarthritis
Zoetis Inc. (NYSE:ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor…
3 months ago benzinga.com
Zoetis' Acquisition of Neogen Genomics Business Faces Regulatory Scrutiny in Australia
The Australian agency is conducting a Phase 2 assessment of Zoetis' $160 million acquisition of Neogen's genomics unit due to competition concerns.
3 months ago benzinga.com
Recent Report Shows That Rep. Byron Donalds Sold Up to $60K Worth of Cadence Design Systems Stock
July 15, 2026 records indicate that Representative Byron Donalds filed a sale of Cadence Design Systems (NASDAQ:CDNS), valued between $4,004 and $60,000. According to the July filing, the transaction…
-
3 months ago benzinga.com
Zoetis Inks Agreement To Acquire Veterinary Teleradiology Services Platform VitalRADS; Financial Terms Undisclosed
Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this…
-
3 months ago benzinga.com
Zoetis Announces EC Grants Marketing Authorization For Poulvac Procerta HVT-ND, Recombinant Vector Vaccine For Protection Of Chickens Against Newcastle Disease And Marek’s Disease Viruses
Recombinant vector vaccine protects chickens against Newcastle disease and Marek's disease in a single doseZoetis Inc. (NYSE:ZTS) today announced that the European Commission (EC) has granted…
-
4 months ago benzinga.com
Barclays Maintains Equal-Weight on Zoetis, Lowers Price Target to $85
Barclays analyst Glen Santangelo maintains Zoetis (NYSE:ZTS) with a Equal-Weight and lowers the price target from $136 to $85.
-
4 months ago benzinga.com
TD Cowen Maintains Buy on Zoetis, Lowers Price Target to $104
TD Cowen analyst Steve Scala maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target from $150 to $104.
-
4 months ago benzinga.com
Stifel Maintains Hold on Zoetis, Lowers Price Target to $85
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target from $95 to $85.
5 months ago benzinga.com
Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick
Cramer says Zoetis has issues. Prefers this stock in animal health industry. Energy Transfer is in a good position.